Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 3, 28 April 2023
Open
Access | Article
Application of Synthetic Biology in SARS-CoV-2 Vaccine Development
* Author to whom correspondence should be addressed.
Abstract
The novel coronavirus SARS-CoV-2 has been spreading at an extraordinary rate since it first appeared in late 2019, causing a large number of infections and deaths. The COVID-19 pan-demic can be successfully controlled most effectively with vaccines, and efforts are being made globally to create new vaccines. Synthetic biology is a design-oriented field that focus-es on creating novel biological functions by discovering, analyzing, and repurposing biologi-cal components. Many SARS-CoV-2 vaccines have been developed using synthetic biology, and the recent approval of a few more vaccines is evidence of the field's continuous growth. This review discusses the use of synthetic biology technology in the creation of several COVID-19 vaccines, concentrating on how to produce vaccines that are safer and more effec-tive through genome optimization and delivery mechanism optimization. Finally, this article highlights some existing problems of synthetic biology technology and provides an outlook on the future development of application this technology in COVID-19 vaccines.
Keywords
SARS-CoV-2, Synthetic Biology, COVID-19 Vaccine
References
1. HY Huang, SH Wang, Y Tang, W Sheng, CJ Zuo, DW Wu, H Fang, Q Du, N Li. “Landscape and progress of global COVID-19 vaccine development.” Human vaccines & immunother-apeutics 17, 3276-3280 (2021).
2. H Fathizadeh, S Afshar, MR Masoudi, P Gholizadeh, M Asgharzadeh, K Ganbarov, Ş Köse, M Yousefi, HS Kafil. “SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effec-tiveness: A review.” International journal of biological macromolecules 188, 740-750 (2021).
3. World Health Organization. (2022, July 22). “COVID-19 vaccine tracker and landscape.” Re-trieved from https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
4. X Tan, JH Letendre, JJ Collins, WW Wong. “Synthetic biology in the clinic: engineering vac-cines, diagnostics, and therapeutics.” Cell 184, 881-898 (2021).
5. Y Wang, C Yang, Y Song, JR Coleman, M Stawowczyk, J Tafrova, S Tasker, D Boltz, R Baker, L Garcia, O Seale, A Kushnir, E Wimmer, S Mueller. “Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.” Proceedings of the National Academy of Sciences of the United States of America 118, e2102775118 (2021).
6. S Torii, C Ono, R Suzuki, Y Morioka, I Anzai, Y Fauzyah, Y Maeda, W Kamitani, T Fukuha-ra, Y Matsuura. “Establishment of a reverse genetics system for SARS-CoV-2 using circu-lar polymerase extension reaction.” Cell reports 35, 109014(2021).
7. TRF Smith, A Patel, S Ramos, D Elwood, X Zhu, J Yan, EN Gary, SN Walker, K Schultheis, M Purwar, Z Xu, J Walters, P Bhojnagarwala, M Yang, N Chokkalingam, P Pezzoli, E Parzych, EL Reuschel, A Doan, N Tursi, M Vasquez, J Choi, E Tello-Ruiz, I Maricic, MA Bah, Y Wu, D Amante, DH Park, Y Dia, AR Ali, FI Zaidi, A Generotti, KY Kim, TA Her-ring, S Reeder, VM Andrade, K Buttigieg, G Zhao, JM Wu, D Li, L Bao, J Liu, W Deng, C Qin, AS Brown, M Khoshnejad, N Wang, J Chu, D Wrapp, JS McLellan, K Muthumani, B Wang, MW Carroll, JJ Kim, J Boyer, DW Kulp, LMPF Humeau, DB Weiner, Bro der-ick. “Immunogenicity of a DNA vaccine candidate for COVID-19.” Nature communica-tions 11, 2601 (2020).
8. L Li, F Saade, N Petrovsky. “The future of human DNA vaccines.” Journal of biotechnology 162, 171-82 (2012).
9. N Pardi, MJ Hogan, D Weissman. “Recent advances in mRNA vaccine technology.” Current opinion in immunology 65, 14-20 (2020).
10. SP Teo. “Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.” Journal of pharmacy practice, 8971900211009650 (2021).
11. PF McKay, K Hu, AK Blakney, K Samnuan, JC Brown, R Penn, J Zhou, CR Bouton, P Rog-ers, K Polra, PJC Lin, C Barbosa, YK Tam, WS Barclay, RJ Shattock. “Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.” Nature communications 11, 3523 (2020).
12. D Pushparajah, S Jimenez, S Wong, H Alattas, N Nafissi, RA Slavcev. “Advances in gene-based vaccine platforms to address the COVID-19 pandemic.” Advanced drug delivery re-views 170, 113-141 (2021).
13. N van Doremalen, T Lambe, A Spencer, S Belij-Rammerstorfer, JN Purushotham, JR Port, VA Avanzato, T Bushmaker, A Flaxman, M Ulaszewska, F Feldmann, ER Allen, H Sharpe, J Schulz, M Holbrook, A Okumura, K Meade-White, L Pérez-Pérez, NJ Edwards, D Wright, C Bissett, C Gilbride, BN Williamson, R Rosenke, D Long, A Ishwarbhai, R Kailath, L Rose, S Morris, C Powers, J Lovaglio, PW Hanley, D Scott, G Saturday, E de Wit, SC Gil-bert, VJ Munster. “ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhe-sus macaques.” Nature 586, 578-582 (2020).
14. C Liu, Q Zhou, Y Li, LV Garner, SP Watkins, LJ Carter, J Smoot, AC Gregg, AD Daniels, S Jervey, D Albaiu. “Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.” ACS central science 6, 315-3313 (2020).
15. Z Liu, W Xu, S Xia, C Gu, X Wang, Q Wang, J Zhou, Y Wu, X Cai, D Qu, T Ying, Y Xie, L Lu, Z Yuan, S Jiang. “RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.” Signal transduction and targeted therapy 5, 282 (2020).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part I
- ISBN (Print)
- 978-1-915371-25-6
- ISBN (Online)
- 978-1-915371-26-3
- Published Date
- 28 April 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/3/20220261
- Copyright
- © 2023 The Author(s)
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited